Short acting GLP-1 receptor agonist (injectable)
Exenatide 5 ug subcutaneous twice daily
EXEN_SC_5UG_BID
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.77 (-1.26 to -0.28) | 0.41 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -0.24 (-1.82 to 1.37) | 0.46 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.34 (0.00 to 16.61) | 0.52 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.73 (0.99 to 2.97) | 0.41 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.60 (0.09 to 2.80) | 0.65 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.22 (1.19 to 4.04) | 0.57 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.18 (0.94 to 4.96) | 0.56 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.68 (1.14 to 6.67) | 0.28 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.87 (0.87 to 4.06) | 0.45 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.72 (0.04 to 10.65) | 0.50 |
| Type 2 diabetes (adults) | Acute kidney injury | longest follow-up | Placebo | HR 0.65 (0.01 to 53.05) | 0.51 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.59 (0.01 to 45.79) | 0.60 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.57 (0.01 to 43.47) | 0.66 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.60 (0.01 to 45.26) | 0.75 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.56 (0.01 to 41.53) | 0.78 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.59 (0.01 to 50.81) | 0.67 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.55 (0.01 to 39.69) | 0.68 |
Trials
- NCT02160990Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying2014 · 20 randomized · 4.29 weeks
- AGAC2Additional GLP-1 Analogue on CSII Treatment for Poorly Controlled Type 2 Diabetic Patients2011 · 51 randomized · 0.43 weeks
- NCT00577824Efficacy and Safety of LY2148568 in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) But Not Well Controlled2008 · 181 randomized · 24 weeks
- NCT00382239A Dose Response Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) But Not Well Controlled2006 · 153 randomized · 12 weeks